--- title: "12 Health Care Stocks Moving In Wednesday's Pre-Market Session" description: "In Wednesday's pre-market session, Liminatus Pharma (LIMN) saw a significant gain of 24.3%, reaching $1.33, while Oncolytics Biotech (ONCY) rose 16.76% to $1.02. Other gainers included Ensysce Bioscie" type: "news" locale: "en" url: "https://longbridge.com/en/news/274808793.md" published_at: "2026-02-04T12:05:36.000Z" --- # 12 Health Care Stocks Moving In Wednesday's Pre-Market Session > In Wednesday's pre-market session, Liminatus Pharma (LIMN) saw a significant gain of 24.3%, reaching $1.33, while Oncolytics Biotech (ONCY) rose 16.76% to $1.02. Other gainers included Ensysce Biosciences (ENSC) up 14.81% and PDS Biotechnology (PDSB) up 10.41%. Conversely, Concord Medical Services (CCM) fell 10.3% to $3.5, and Boston Scientific (BSX) dropped 9.27% to $83.13. Notable declines also included CDT Equity (CDT) and VSee Health (VSEE). ### Gainers - **Liminatus Pharma** (NASDAQ:LIMN) stock increased by 24.3% to $1.33 during Wednesday's pre-market session. The company's market cap stands at $28.9 million. - **Oncolytics Biotech** (NASDAQ:ONCY) shares rose 16.76% to $1.02. The company's market cap stands at $94.4 million. - **Ensysce Biosciences** (NASDAQ:ENSC) stock rose 14.81% to $0.7. The company's market cap stands at $2.1 million. - **PDS Biotechnology** (NASDAQ:PDSB) shares rose 10.41% to $0.84. The market value of their outstanding shares is at $41.8 million. - **Valneva** (NASDAQ:VALN) stock increased by 10.36% to $10.01. The market value of their outstanding shares is at $786.4 million. - **Lunai Bioworks** (NASDAQ:LNAI) stock increased by 10.01% to $0.78. The market value of their outstanding shares is at $16.6 million. ### Losers - **Concord Medical Services** (NYSE:CCM) shares declined by 10.3% to $3.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $169.3 million. - **Boston Scientific** (NYSE:BSX) shares fell 9.27% to $83.13. The market value of their outstanding shares is at $135.8 billion. As per the press release, Q4 earnings came out today. - **CDT Equity** (NASDAQ:CDT) stock declined by 9.03% to $1.21. The company's market cap stands at $3.0 million. - **VSee Health** (NASDAQ:VSEE) shares declined by 7.43% to $0.32. The company's market cap stands at $11.3 million. - **Cencora** (NYSE:COR) stock decreased by 6.84% to $337.01. The market value of their outstanding shares is at $70.3 billion. The company's, Q1 earnings came out today. - **NewGenIvf Group** (NASDAQ:NIVF) shares fell 6.26% to $1.2. The company's market cap stands at $1.2 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/ This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md) - [ONCY.US - Oncolytics Biotech](https://longbridge.com/en/quote/ONCY.US.md) - [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [ENSC.US - Ensysce Biosciences](https://longbridge.com/en/quote/ENSC.US.md) - [XHS.US - SPDR S&P Health](https://longbridge.com/en/quote/XHS.US.md) - [PDSB.US - PDS Biotechnology](https://longbridge.com/en/quote/PDSB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Oncolytics Biotech’s Top Brass Make Bold Insider Move | Oncolytics Biotech (ONCY) executives made significant insider purchases on February 13, 2026, indicating confidence in t | [Link](https://longbridge.com/en/news/275966193.md) | | EXCLUSIVE: Penny Stock VSEE Health Teams Up With GoMyRx To Expand Telehealth Drug Delivery | VSEE Health Inc. has partnered with GoMyRx to enhance telehealth services by integrating prescription fulfillment and me | [Link](https://longbridge.com/en/news/274981770.md) | | FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer | The FDA has approved Merck's KEYTRUDA regimen for treating adults with PD-L1 positive platinum-resistant ovarian cancer. | [Link](https://longbridge.com/en/news/275598070.md) | | Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy | Solid Biosciences Inc announced positive feedback from a Type C meeting with the FDA regarding its SGT-003 gene therapy | [Link](https://longbridge.com/en/news/275336174.md) | | Enanta Pharmaceuticals to Present Preclinical Data for EDP-978 at AAAAI Annual Meeting | Enanta Pharmaceuticals Inc. will present preclinical data for its KIT inhibitor, EDP-978, at the AAAAI Annual Meeting fr | [Link](https://longbridge.com/en/news/275452910.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.